HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scardino, A. Articles by Kosmatopoulos, K. Search for Related Content PubMed PubMed Citation Articles by Scardino, A. Articles by Kosmatopoulos, K.

HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy¹

Antonio Scardino^2,*, David-Alexandre Gross^2,*, Pedro Alves^*, Joachim L. Schultze, Stéphanie Graff-Dubois^*, Olivier Faure^*, Sophie Tourdot^*, Salem Chouaib^*, Lee M. Nadler, François A. Lemonnier, Robert H. Vonderheide^3,, Angelo A. Cardoso^3, and Kostas Kosmatopoulos^4,*

^* Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Gustave Roussy, Villejuif, France; Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; and Unité d’Immunité Cellulaire Antivirale, Departement Sida Retrovirus, Institut Pasteur, Paris, France

Tolerance to tumor-nonmutated self proteins represents a major obstacle for successful cancer immunotherapy. Since this tolerance primarily concerns dominant epitopes, we hypothesized that targeting cryptic epitopes that have a low affinity for HLA could be an efficient strategy to breach the tolerance to tumor Ags. Using the P1Y heteroclitic peptide approach, we identified low affinity cryptic HLA-A*0201-restricted epitopes derived from two widely expressed tumor Ags, HER-2/neu and hTERT. The P1Y variants of four HER-2/neu (neu₃₉₁, neu₄₀₂, neu₄₆₆, neu₆₅₀)- and two hTERT (hTERT₅₇₂ and hTERT₉₈₈)-derived low affinity peptides exhibited strong affinity for HLA-A*0201 and stimulated specific CTL from healthy donor PBMCs. These CTL specifically recognized HER-2/neu- and hTERT-expressing tumor cells of various histological origins. In vivo studies showed that HLA-A*0201 transgenic HHD mice vaccinated with the P1Y variant peptides generated CTL that specifically lysed Ag-expressing tumor cells, thus recognizing the cognate endogenous Ags. These results suggest that heteroclitic variants of low affinity, cryptic epitopes of widely expressed tumor Ags may serve as valid tools for tumor immunotherapy.

This article has been cited by other articles:

				A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells Clin. Cancer Res., July 1, 2009; 15(13): 4499 - 4507. [Abstract] [Full Text] [PDF]

				A. Scardino, M. Alimandi, P. Correale, S. G. Smith, R. Bei, H. Firat, M. G. Cusi, O. Faure, S. Graf-Dubois, G. Cencioni, et al. A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge Cancer Res., July 15, 2007; 67(14): 7028 - 7036. [Abstract] [Full Text] [PDF]

				I. Bolonaki, A. Kotsakis, E. Papadimitraki, D. Aggouraki, G. Konsolakis, A. Vagia, C. Christophylakis, I. Nikoloudi, E. Magganas, A. Galanis, et al. Vaccination of Patients With Advanced Non-Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide J. Clin. Oncol., July 1, 2007; 25(19): 2727 - 2734. [Abstract] [Full Text] [PDF]

				R. Singh and Y. Paterson Vaccination Strategy Determines the Emergence and Dominance of CD8+ T-Cell Epitopes in a FVB/N Rat HER-2/neu Mouse Model of Breast Cancer. Cancer Res., August 1, 2006; 66(15): 7748 - 7757. [Abstract] [Full Text] [PDF]

				H. Zhu, K. Liu, J. Cerny, T. Imoto, and K. D. Moudgil Insertion of the Dibasic Motif in the Flanking Region of a Cryptic Self-Determinant Leads to Activation of the Epitope-Specific T Cells J. Immunol., August 15, 2005; 175(4): 2252 - 2260. [Abstract] [Full Text] [PDF]

				A. Machlenkin, A. Paz, E. Bar Haim, O. Goldberger, E. Finkel, B. Tirosh, I. Volovitz, E. Vadai, G. Lugassy, S. Cytron, et al. Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy Cancer Res., July 15, 2005; 65(14): 6435 - 6442. [Abstract] [Full Text] [PDF]

				A. Michael, G. Ball, N. Quatan, F. Wushishi, N. Russell, J. Whelan, P. Chakraborty, D. Leader, M. Whelan, and H. Pandha Delayed Disease Progression after Allogeneic Cell Vaccination in Hormone-Resistant Prostate Cancer and Correlation with Immunologic Variables Clin. Cancer Res., June 15, 2005; 11(12): 4469 - 4478. [Abstract] [Full Text] [PDF]

				M. A. Lyman, C. T. Nugent, K. L. Marquardt, J. A. Biggs, E. G. Pamer, and L. A. Sherman The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice J. Immunol., March 1, 2005; 174(5): 2563 - 2572. [Abstract] [Full Text] [PDF]

				J. Bae, J. A. Martinson, and H. G. Klingemann Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies Clin. Cancer Res., February 15, 2005; 11(4): 1629 - 1638. [Abstract] [Full Text] [PDF]

				P. Sinha, H. H. Chi, H. R. Kim, B. E. Clausen, B. Pederson, E. E. Sercarz, I. Forster, and K. D. Moudgil Mouse Lysozyme-M Knockout Mice Reveal How the Self-Determinant Hierarchy Shapes the T Cell Repertoire against This Circulating Self Antigen in Wild-Type Mice J. Immunol., August 1, 2004; 173(3): 1763 - 1771. [Abstract] [Full Text] [PDF]

				M. L. Disis, K. Schiffman, K. Guthrie, L. G. Salazar, K. L. Knutson, V. Goodell, C. dela Rosa, and M. A. Cheever Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein--Based Vaccine J. Clin. Oncol., May 15, 2004; 22(10): 1916 - 1925. [Abstract] [Full Text] [PDF]

				T. D. Schell In Vivo Expansion of the Residual Tumor Antigen-Specific CD8+ T Lymphocytes That Survive Negative Selection in Simian Virus 40 T-Antigen-Transgenic Mice J. Virol., February 15, 2004; 78(4): 1751 - 1762. [Abstract] [Full Text] [PDF]

				R. H. Vonderheide, S. M. Domchek, J. L. Schultze, D. J. George, K. M. Hoar, D.-Y. Chen, K. F. Stephans, K. Masutomi, M. Loda, Z. Xia, et al. Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes Clin. Cancer Res., February 1, 2004; 10(3): 828 - 839. [Abstract] [Full Text] [PDF]

				V. Apostolopoulos, E. Yuriev, P. A. Ramsland, J. Halton, C. Osinski, W. Li, M. Plebanski, H. Paulsen, and I. F. C. McKenzie A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor PNAS, December 9, 2003; 100(25): 15029 - 15034. [Abstract] [Full Text] [PDF]

				A. M. Ercolini, J.-P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice J. Immunol., April 15, 2003; 170(8): 4273 - 4280. [Abstract] [Full Text] [PDF]